Skip to main content
. 2022 Mar 24;94(7):3184–3191. doi: 10.1002/jmv.27724

Table 4.

Adverse drug reactions of the patient with confirmed COVID‐19

FVP group (n = 32) LPV/RTV group (n = 32) p
Any 8 (25.0) 10 (32.3) 0.585
Gastrointestinal disorders 4 (12.5) 4 (12.9) 0.999
Abnormal liver function tests 0 (0.0) 1 (3.1) 0.999
Blood pressure increase 0 (0.0) 0 (0.0) 0.999
Bradycardia 1 (3.1) 0 (0.0) 0.999
Serum creatinine elevation 0 (0.0) 2 (7.1) 0.214
Leukopenia 4 (16.0) 3 (10.0) 0.689
Hematuria 0 (0.0) 0 (0.0) 0.999
Rash 0 (0.0) 0 (0.0) 0.999

Note: Values were expressed as n (%).

Data were collected within 7 days of randomization.

Comparison between groups was performed using Fisher's exact test.